NCT03124199View on ClinicalTrials.gov

Rifaximin Associated With Classic Triple Therapy for the Eradication of Helicobacter Pylori Infection

PHASE3CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

February 28, 2014

Primary Completion Date

March 31, 2015

Study Completion Date

June 30, 2015

Conditions
Bacterial Infection Due to Helicobacter Pylori (H. Pylori)
Interventions
DRUG

Rifaximin

Rifaximin 400 mg/8 h added to the standard triple therapy

Trial Locations (1)

28006

Hospital Universitario de La Princesa, Madrid

All Listed Sponsors
lead

Fundación de Investigación Biomédica - Hospital Universitario de La Princesa

OTHER

NCT03124199 - Rifaximin Associated With Classic Triple Therapy for the Eradication of Helicobacter Pylori Infection | Biotech Hunter | Biotech Hunter